Home/Pipeline/C1-based Therapeutic Antigen

C1-based Therapeutic Antigen

Infectious Disease

Phase ICompleted

Key Facts

Indication

Infectious Disease

Phase

Phase I

Status

Completed

Company

Dyadic

About Dyadic

Dyadic is an industrial biotechnology company with a mission to expand access to essential proteins by making biomanufacturing faster, more affordable, and scalable. Its core achievement is the development of the C1 and Dapibus™ filamentous fungal platforms, proven at commercial scales over 100,000L and validated in a Phase I clinical trial. The company's strategy is to partner across industries, offering flexible engagement models—from selling recombinant proteins to licensing its platforms—to drive adoption and revenue.

View full company profile

Therapeutic Areas

Infectious Disease General Biologics

Other Infectious Disease Drugs

Drug	Company	Phase	Status
Vaccine Platform	Biolingus	Research	Active
Pipeline Antibiotics	BioQ Pharma	Unknown	Active
Antivirals Platform	Qubit Pharmaceuticals	Discovery	Active
Antibiotic Development Program	AF ChemPharm	Pre-clinical	Active
Prophylactic Vaccine Development	ImmuneSpec	Service	Active
Optimized VHH vs. SARS-CoV-2	Ordaos Bio	Pre-clinical	Active
Undisclosed Vaccine Program(s)	Brazos Biomedical	Pre-clinical	Active
Undisclosed Asset 1	Uvax Bio	Research	Active
Undisclosed Asset 2	Uvax Bio	Research	Active
Undisclosed Asset 3	Uvax Bio	Research	Active
Vaccine Immune Response (SARS-CoV-2)	CellChorus	Preclinical	Active
XmAb®662	Xencor	Preclinical	Active